Effects of Stimulant Dependence on Human Striatal Dopamine System - 15
Information source: National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Amphetamine-Related Disorders; Tobacco Use Disorder
Phase: Phase 1
Status: Active, not recruiting
Sponsored by: National Institute on Drug Abuse (NIDA) Official(s) and/or principal investigator(s): Walter Ling, M.D., Principal Investigator, Affiliation: Friends Research Institute, Inc.
Summary
The purpose of this study is to determine whether DAT availability, assessed by WIN binding,
in the striatum is altered in cocaine or methamphetamine dependence. To determine whether
DA synthesis capacity, assessed by FDOPA uptake, in the striatum is altered in Coc or Meth
dependence. To determine whether the PET tracers, WIN or FDOPA, will differentiate Meth
induced alterations from those induced by Coc use. To determine whether the PET
characterization of striatal alterations observed at 3-5 days since last drug use persists
at least 3 months after last drug use.
Clinical Details
Official title: Effects of Stimulant Dependence on Human Striatal Dopamine System
Study design: Masking: Open Label, Primary Purpose: Treatment
Detailed description:
4-5 Day inpatient study. Participant will have scanned pictures (MRI & PET scans) taken of
their brain after being injected with a small amount of WIN, a radioactive substance.
Participants give daily urine samples and fill out health related questionnaires. It is
important to determine whether the alterations characterized within one week of last drug
use persist over a longer time period. Based on results of the studies from aims 1 & 2, we
will decide which of the 2 probes, WIN or FDOPA-PET is the more sensitive index of
stimulant-dependency-induced changes.
Eligibility
Minimum age: 21 Years.
Maximum age: 50 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
M/F, ages 21-50. Meet DSM-IV criteria for methamphetamine and nicotine dependence. Agree
to conditions of the study and sign informed consent.
Exclusion Criteria:
Psychiatric disorder that requires medication therapy. History of seizures. Pregnant
and/or nuring women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics.
Acute hepatitis. Other medical condtions that deem participation to be unsafe.
Locations and Contacts
Friends Research Institute, Los Angeles, California 90025, United States
Additional Information
Starting date: March 1999
Last updated: November 3, 2005
|